Vaxcyte (NASDAQ:PCVX) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.
Profitability
This table compares Vaxcyte and Beam Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Vaxcyte | N/A | N/A | N/A |
Beam Therapeutics | -529,075.00% | -103.41% | -48.05% |
Insider and Institutional Ownership
74.1% of Vaxcyte shares are owned by institutional investors. Comparatively, 49.8% of Beam Therapeutics shares are owned by institutional investors. 0.7% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Vaxcyte and Beam Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Vaxcyte | N/A | N/A | $-50,270,000.00 | N/A | N/A |
Beam Therapeutics | $20,000.00 | 212,996.07 | $-78,330,000.00 | ($14.05) | -5.23 |
Vaxcyte has higher earnings, but lower revenue than Beam Therapeutics.
Analyst Recommendations
This is a summary of current recommendations and price targets for Vaxcyte and Beam Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Vaxcyte | 0 | 0 | 4 | 0 | 3.00 |
Beam Therapeutics | 0 | 3 | 3 | 0 | 2.50 |
Vaxcyte presently has a consensus price target of $48.00, indicating a potential upside of 103.22%. Beam Therapeutics has a consensus price target of $96.00, indicating a potential upside of 30.63%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Beam Therapeutics.
Summary
Vaxcyte beats Beam Therapeutics on 8 of the 10 factors compared between the two stocks.